-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A recent study published in Journal of Clinical Endocrinology and Metabolism, a authoritative journal in the field of endocrine and metabolic diseases, assessed whether long-term blood glucose variability (GV) is associated with vascular complications in people with type 2 diabetes.
In this post-morthmic field test analysis, the researchers calculated GV using the standard deviation and coefficient of variation (CV) of HbA1c and antholine blood sugar, and compared the differences between the four parts of the variables and the baseline variables by card square and variance analysis.
researchers analyzed the association between baseline to two-year GV and subsequent vascular and mortality outcomes using the iconic Logistic and Cox proportional risk regressions.
factors associated with higher GVs include younger age, men, longer duration of diabetes, and higher drug use.
HbA1c and short-bed blood sugar CV were associated with an increased risk of microvascular complications (HR was 1.02 (95%CI was 1.01-1.03), p.lt;0.01; HR was 1.01 (95% CI was 1.00-1.01), p.lt;0.001).
HbA1c and anthotic blood sugar CV were associated with an increase in cardiovascular disease (HR was 1.02 (95%CI was 1.00-1.04);
HbA1c CV is associated with an increase in stroke (HR is 1.03, (95% CI is 1.01-1.06), p.lt;0.01).
blood sugar CV was associated with an increase in coronary artery events (HR was 1.01, (95% CI was 1.00-1.02), p.lt;0.05).
HbA1c and Glycemic CV were associated with total mortality (HR was 1.04, (95% CI was 1.02-1.06); HR is 1.01 (95%CI is 1.01-1.02), both p.lt;0.001) and non-cardiovascular mortality (HR is 1.05, (95% CI is 1.03-1.07; HR 1.02 (95% CI 1.01-1.03), both associated with an increase in p.lt;0.001).
HbA1c CV is associated with coronary heart disease mortality (HR is 1.04, (95% CI is 1.01-1.07), p.lt;0.05).
that long-term glycemic GV is associated with an increased risk of vascular outcomes in people with type 2 diabetes.
.
